CNTB NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Connect Biopharma Holdings Ltd · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.02 USD
-5.6% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -18.1% below the Trend Line and sits at 30.5% of its 52-week range. The latest completed week returned -5.6%, after a -17.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 63/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 8d.

Setup score 30 out of 100
Latest Close 2.02 USD 31 Jul 2026
1W Return -5.6% latest completed week
4W Return -17.9% short-term follow-through
12W Return -14.4% quarterly tape
Trend Breadth 14.6% 7 of 48 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • Next-week expectancy is positive at 56.76% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.6% Latest completed week; four-week move -17.9%. Indicator stack 8/40 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 56.76% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 63/100 conviction; expected move 44.2%. News sentiment 51/100 41 relevant articles in the latest sentiment read. Event risk 8d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -18.1% below the Trend Line and sits at 30.5% of its 52-week range. The latest completed week returned -5.6%, after a -17.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2012-week average 0.34

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -17.9% over four weeks, -14.4% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.6%
4W-17.9%
12W-14.4%
26W-15.8%
52W-
Active trend streak0 weeks
Active weeks in one year7
Trend breadth14.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.70Latest activity-pressure read.
Pressure change27.5%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 73% Model confidence 69%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength67/100Blend of value, momentum, and quality. Underlying universe rank 34; rank 1 is best.
Value58/100Relative valuation strength. Underlying universe rank 43; rank 1 is best.
Quality56/100Profitability and accounting quality. Underlying universe rank 45; rank 1 is best.
Momentum59/100Medium-term price momentum. Underlying universe rank 42; rank 1 is best.
Growth58/100Revenue and earnings growth. Underlying universe rank 43; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
510.8x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-69.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
25.7%
Gross profit retained from each unit of revenue.
Operating margin
-26188.8%
Operating profit retained from revenue.
Free-cash-flow margin
-22851.0%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-99.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

CNTB shows volatility options pressure with a 63/100 conviction score, put-call volume ratio of 0.00, expected move of 44.2%, and Sharemaestro trend signal inactive.

Conviction63/100
Expected move44.2%
Put/call volume0.00
Pressure100
Speculation51
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 41 relevant articles.

5 positive · 35 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings8dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move44.2%Nearest-chain priced movement where available.
52-week drawdown-47.1%Distance below the 52-week high.
13-week volatility7.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+25.0%Week of 27 Mar.
Worst week-13.3%Week of 3 Apr.
Latest week-5.6%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains6
Flat weeks0
Modest losses4
Sharp losses10
Recent vol7.0%13-week weekly-return volatility.
Base vol12.4%52-week weekly-return volatility.
Up/down split22/25Count of positive and negative weeks in the 52-week window.
Average skew10.2% / -7.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape34/100

Trend, activity pressure, participation, and risk combine to a 34/100 tape read.

 Indicator analysis12/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.20; No reversal markers Next-Week ExpectancyPositive 56.76%

Next-week expectancy is positive with a 56.76% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 47; Small Cap Core rank 49 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options39/100

CNTB shows volatility options pressure with a 63/100 conviction score, put-call volume ratio of 0.00, expected move of 44.2%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 44.2% Sentiment51/100

Weighted news tone is neutral across 41 relevant articles.

Connect Biopharma Holdings Ltd (CNTB) Institutional Confidence Insiders50/100

No recent insider transaction evidence is stored.

 Earnings8d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.02 USD-5.6%2.47 USD2.31 USD-0.70-957.4KOff
24 Jul 20262.14 USD-10.1%2.48 USD2.31 USD-0.62-1.5MOff
17 Jul 20262.38 USD-5.2%2.50 USD2.32 USD-0.55-2.8MOff
10 Jul 20262.51 USD2.0%2.50 USD2.32 USD-0.75-4.6MOff
3 Jul 20262.46 USD12.3%2.50 USD2.31 USD-0.97-1.8MOff
26 Jun 20262.19 USD9.5%2.49 USD2.31 USD-1.03-4.5MOff
19 Jun 20262.00 USD-5.7%2.52 USD2.31 USD-1.03-1.1MOff
12 Jun 20262.12 USD-2.3%2.55 USD2.32 USD-1.00-1.2MOff
5 Jun 20262.17 USD-12.9%2.55 USD2.32 USD-0.96-1.4MOff
29 May 20262.49 USD6.0%2.53 USD2.33 USD-0.95-1.1MOff
22 May 20262.35 USD-1.3%2.50 USD2.32 USD-0.94-673.2KOff
15 May 20262.38 USD0.8%2.48 USD2.32 USD-0.70-834.0KOff
8 May 20262.36 USD-4.5%2.46 USD2.32 USD-0.37-698.2KOn
1 May 20262.47 USD-2.0%2.44 USD2.32 USD-0.04-558.8KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.